ECCO essential requirements for quality cancer care: Melanoma

Wouters, Michel W. J. M.; Michielin, Olivier; Bastiaannet, E.; Beishon, Marc; Catalano, Orlando; Marmol, Véronique Del; Delgado-Bolton, Roberto; Dendale, R.; Trill, María Die; Ferrari, Andrea; Forsea, Ana Maria; Kreckel, Hannelore; Lövey, József; Luyten, Gré P.M.; Massi, Daniela; Mohr, Peter; Oberst, Simon; Pereira, Philippe L.; Prata, João Paulo Paiva; Rutkowski, Piotr; Saarto, Tiina; Sheth, Sapna; Spurrier-Bernard, Gilly; Vuoristo, Meri Sisko; Costa, Alberto; Naredi, Peter

doi:10.1016/j.critrevonc.2017.12.020

Cited by 48 publications

(53 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Close cooperation between pediatric oncologists/surgeons and experts at specialist adult melanoma centers has been recommended. 15 In particular, cooperative networking is essential for clinical studies. 8 Two international early-phase trials on new agents (vemurafenib in one trial, ipilimumab in the other) were both terminated prematurely due to an insufficient recruitment of young melanoma patients.…”

mentioning

confidence: 99%

Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records

Ferrari

Bernasconi

Sironi

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

23 per 100 000 population/year, respectively (https://gco.iarc.fr/). The risk of developing melanoma increases with age and is therefore considered rare in the pediatric world. While it is very rarely seen in children under 10 years old (the annual incidence is around 0.7-0.8 per million), melanoma diagnoses increase after puberty, with an incidence of 14 and 23 per million in adolescent males and females, 1 respectively. According to the consensus promoted by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) and the European Union Joint Action on Rare Cancers (JARC), "very rare pediatric cancers" are those with an annual incidence of less than two per million. 2 This means that melanoma must be classified as rare in children, but this may not be true for adolescents. Melanoma in young patients is clinically challenging because it may have different clinical features from those usually seen in adults (for example, it might appear amelanotic or raised). 3-5 Data sharing is not applicable to this article. Authors do not have permission to share the data.

show abstract

mentioning

confidence: 99%

Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records

Ferrari

Bernasconi

Sironi

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides well-organised healthcare professional teams, a healthcare system based on patient-centricity must also establish better patient–physician relationships and involvement of patients in the decision-making process. Patients should be empowered and educated to participate in scientific and policy discussion, advocacy patient groups and committees as ‘patient experts’ [23, 29, 36]. In this context, patient-reported outcome measures (PROMs) are being extensively used to create the foundation for the action of this multidisciplinary approach.…”

Section: Integrated Care For Patients With Skin Cancermentioning

confidence: 99%

“…Although the ‘ one-size-fits-all ’ view is no longer applicable, it is challenging to define measures that apply to all genetic and therapeutic characteristics of each patient and bring real-life benefits to every patient [29]. Nonetheless, providing care to a selected group of patients (personalised medicine) is a way to improve results, in terms of quality, patient’s satisfaction, treatment access and efficiency [36, 37]. PROMs that capture a comprehensive perspective of the patient, considering the impact of cancer treatments on health outcomes, such as patient satisfaction, perceived quality of care, patient outcomes, symptom management and acceptability [38].…”

Section: Integrated Care For Patients With Skin Cancermentioning

confidence: 99%

Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?

Redondo

Ribeiro

Lopes

et al. 2019

ecancer

View full text Add to dashboard Cite

Patients with skin cancer should be treated in healthcare units that ensure holistic and multidisciplinary approaches. Current healthcare units, especially those dedicated to cancer care, must evolve to integrated patient-centred systems. The current review presents a holistic health services perspective towards managing patients with melanoma of the skin, based on a literature search. It includes a detailed discussion on how this could impact on the patient, his or her quality of life and on service providers. Data from a multidisciplinary integrated practice unit, specialised in skin cancer, were also discussed, namely, for outcomes measurements, access to innovative treatments, valuebased healthcare, patient centricity and use of integrated systems. Epidemiology data, including disease determinants and risk factors, play an important role in defining measures, resources and management of these integrated cancer units. To optimise effective care and improve survival outcomes, integrated cancer clinics should comprise, in a patient-centred way, innovative treatments and technologies, along with continuous training and creation of multidisciplinary units of healthcare professionals. Measurement of outcomes, such as clinical, quality of life and cost, is decisive in determining affordability and access to the best available state-of-the-art care. Besides, treatment of melanoma has significantly improved over recent years, but with increasing costs, which brings a challenging mission to guarantee access to treatment and quality care. Value-based healthcare allows the achievement of better health outcomes and higher quality services while reducing the costs associated with the full-care cycle. Therefore, current healthcare systems should develop in line with health institutions' organisation and culture, increasing adherence to best practices and create value.

show abstract

“…Ulceration, tumor thickness, node involvement, and tumor stage influence prognosis (Brecht et al 2015;Ferrari et al 2014). Thus, as no specific treatment recommendations do exist, the management of pediatric melanoma basically follows the adult guidelines (Garbe et al 2016;Wouters et al 2018).…”

Section: Clinical Presentation and Risk Factorsmentioning

confidence: 99%